Sodium Dodecanoate
CAS 629-25-4
Sodium Dodecanoate (CAS 629-25-4) is a pharmaceutical compound with 1 bioactivity target and 0 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Bioactivity & Target Interactions
Target-level activity records with assay counts, activity type, and measured value where present.
| Target | Activity | Value | Assays | Organism |
|---|---|---|---|---|
| - | Ki | 20800 nM | 1 | - |
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Sodium Dodecanoate used for in pharmaceutical contexts?
Sodium Dodecanoate (CAS 629-25-4) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Sodium Dodecanoate?
No adverse-event association or SIDER side-effect rows are rendered for Sodium Dodecanoate in this page query. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Sodium Dodecanoate also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for Sodium Laurate with EU status "permitted".
What clinical phase is Sodium Dodecanoate in?
No phase 1-4 clinical development badge is rendered for Sodium Dodecanoate because the matched compound identifier rows do not contain a max-phase value.